Alnylam receives U.

Patent allowance for LNP platform Alnylam Pharmaceuticals, Inc. , a leading RNAi therapeutics company, announced today that the United States Patent and Trademark Office has released a Notice of Allowance for patent application number 12/813,448, covering the company’s proprietary second era lipid nanoparticle platform, like the ‘MC3’ lipid. ‘We are very happy with the USPTO’s allowance of claims for this important patent related to our second generation LNPs, hence acknowledging the novelty of the MC3 lipid for systemic delivery of RNAi therapeutics,’ said Laurence Reid, Ph.D., Senior Vice Chief and President Business Officer of Alnylam. ‘Importantly, these novel LNPs exhibit significant improvements in potency and therapeutic index for RNAi therapeutics, as evidenced by our recent human being data with ALN-PCS, and also define Alnylam’s LNP platform for advancement of ALN-TTR02 and possibly other ‘Alnylam 5×15′ programs.’..For more info associated with Uppsala Biobank please check out For more info on sample storage space solutions for biobanking applications please get in touch with Micronic European countries B.V. today on +31-320-277070 / email product or Micronic America LLC on +1-484-480-3372. Micronic is a respected global supplier of protected sample storage answers to Biobanking and laboratory services. Focused on the production and style of innovative sample storage space solutions during the last 25 years, Micronic is uniquely in a position to give laboratories the professional advice to greatly help them safeguard among its most effective assets – its samples.. AnaptysBio enters new strategic alliances for antibody discovery AnaptysBio, Inc., a privately-held therapeutic antibody company, today announced the initiation of new strategic alliances with two partners: Novartis and an undisclosed second pharmaceutical organization.